Drug Trial Radar · NCT07714187
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Oct 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- SecuraBioIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.
Conditions
- Mycosis Fungoides
- Cutaneous T-cell Lymphoma
Interventions
DuvelisibDrug
Topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline through Day 114
- Local Skin Reactions to Duvelisib Topical GelTime frame: After each treatment administration up to Day 114
- Maximum Tolerated Dose (MTD) of Duvelisib Topical GelTime frame: Up to 28 days
- Recommended Phase 2 Dose (RP2D) of Duvelisib Topical GelTime frame: Up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.